On November 20, the University of Minnesota MN-REACH program (a NIH-funded Research Evaluation And Commercialization Hub), will host former Eli Lilly executive Bernard Munos to discuss his recent findings on what’s wrong with Big Pharma R&D, and how a new, more nimble, largely ousourced model may offer greater potential for breakthrough drugs in less time at lower cost. The key elements of the new model: networks of academic researchers and startups interacting with (but not within) large pharmaceutical companies.
He’s got a radical perspective, but you can’t deny that the current system leaks a lot of time, money and talent.
Bernard Munos is a Senior Fellow at FasterCures, a Center of the Milken Institute, and founder of InnoThink, a consultancy focused on pharmaceutical innovation. His research has been published in Nature and Science, and profiled by Forbes magazine. Munos advises companies, non-profit and government-funded research organizations on being better innovators. The popular industry newsletter FiercePharma has named him one of the 25 most influential people in biopharma.